Preclinical studies have shown that the delivery of IL-2/anti-IL-2-antibody complexes stimulates Treg expansion and reduces disease in models of T1DM, experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis, and angiotensin II-induced aortic stiffening [49–51]. Here, IL2 is linked to type 1 diabetes mellitus.